Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “KALA.”

Based in Waltham, Massachusetts, Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles technology, with an initial focus on the treatment of eye diseases. 

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Marcel Fausten and associate Andrew J. Terjesen. Partner Frank J. Azzopardi and associate Arjun Ravi provided intellectual property and technology advice. Partner Kathleen L. Ferrell and associate Gil Savir provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post